Clinical trials are complicated and often the results can be even more so. Close monitoring of the interactions between patients, diseases, conditions and drugs for extended periods of time and the various questions posed in order to prove or disprove safety and efficacy of particular treatments result in an accurate yet highly complex mountain of data.
Clinical trials are conducted to answer a specific question about a treatment, usually related to safety and efficacy. This involves the development of a hypothesis, and then the running of clinical trials to collect data and to demonstrate the validity of the hypothesis using statistical analysis.
As many of you may know, this week saw Clinuvel hold its Annual General Meeting in the Melbourne Town Hall. As managing director I welcome these opportunities where I am able to meet and talk to the people whom Clinuvel considers integral to the company and its existence; the Board of Directors sees Clinuvel’s investors as unique. In Clinuvel, an investor has to fundamentally believe in the premise of offering pharmaceutical photoprotection, a novel option, an innovative approach to skin disorders.
The research that underpins
A new initiative has just launched in the UK with the goal of increasing awareness and support for the more widespread use of 
Those of you that follow pharmaceutical development and Clinuvel in particular will know that we recently presented at Rodman and Renshaw’s 11th Annual Healthcare Conference in New York. It’s serendipitous that the following week found another conference taking place in the same city, although involving a rather different topic. The coincidence draws attention to a connection that is of increasing urgency and importance.
A most interesting movement that’s gathering steam within pharmaceutical development is that of Green Pharma.
During more than a decade of clinical research on Clinuvel’s proprietary drug 
